New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Low-Molecular-Weight Heparin Versus Aspirin for Acute Ischemic Stroke with Large Artery Occlusive Disease
Stroke 43:346-349,293, Wang,Q.S,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Insufficient Platelet Inhibition is Related to Silent Embolic Cerebral Infarctions After Coronary Angiography
Stroke 43:727-732, Kim,B.J.,et al, 2012
Clinical Reasoning: A Middle-Aged Woman with Progressive Symmetric Weakness and a CSF Pleocytosis
Neurol 78:e88-e92, Marks,D.,et al, 2012
Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012
Dual or Mono Antiplatelet Therapy for Patients with Acute Ischemic Stroke or Transient Ischemic Attack
Stroke 43:1058-1066, Geeganage,C.M.,et al, 2012
Anticoagulation for Cerebral Venous Sinus Thrombosis
Stroke 43:e41-e42, Coutinho,J.M.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Bridging Therapy in Acute Ischemic Stroke
Stroke 43:1302-1308, Mazighi,M.,et al, 2012
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
BMJ 342:d1938, McArthur, K.S.,et al, 2011
Anticoagulation in Patients with Stroke With Infective Edocarditis Is Safe
Stroke 42:1795-1796,1799, Rasmussen, R.V., 2011
Anticoagulation Should Not Be Used in Most Patients With Stroke With Infective Endocarditis
Stroke 42:1797-1798,1799, Sila, C., 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Cerebral Venous Sinus Thrombosis Associated with Cerebral Hemorrhage Is Anticoagulant Treatment Safe?
The Neurologist 17:208-210, Fuentes, B.,et al, 2011
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
Lancet 377:2013-2022, Bousser, M.G.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis
Stroke 42:2333-2335, Seet, R.C.S.,et al, 2011
Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease
Stroke 42:e420-e463, Brott, T.G.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Efficacy and Safety of Combination Antiplatelet Therapies in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Stroke 42:2883-2890, Kwon, S.U.,et al, 2011
Chronic Heart Failure and Ischemic Stroke
Stroke 42:2977-2982, Haeusler, K.G.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Clinical Characteristics of Pediatric-onset Neuro-Behcet Disease
Neurol 77:1900-1905, Uludiz, D.,et al, 2011
Warfarin-Related Intraventricular Hemorrhage
Neurol 77:1840-1846, Biffi, A.,et al, 2011
Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Beh�et Disease: Evolution of Clincal Manifestations
Medicine 90:125-132, Ideguchi,H.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Increased Risk of Stroke After Discontinuation of Acetlysalicylic Acid: A UK Primary Care Study
Neurol 76:740-746, Rodr�guez,L.A.G.,et al, 2011
Hemorrhagic Transformation of Childhood Arterial Ischemic Stroke
Stroke 42:941-946, Beslow,L.A.,et al, 2011
Bridging Intravenous-Inta-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study
Stroke 42:993-997, 880, Rubiera,M.,et al, 2011
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator
Stroke 42:1041-1045, Vergouwen,M.D.I.,et al, 2011
Cervical Carotid Artery Disease in Sickle Cell Anemia: Clinical and Radiological Features
Blood 118:6192-6199, Telfer, P.T.,et al, 2011